相关实验视频
Updated: Jun 18, 2025

09:38
Comprehensive Analysis of Drug Response using the FLICK Assay
Published on: June 6, 2025
49
对20家顶级制药公司 (2014-2023) 的FDA批准进行比较分析 (2014-2023年)
Alexander Schuhmacher1, Oliver Gassmann2, Markus Hinder3
1Technische Hochschule Ingolstadt, THI Business School, Esplanade 10, D-85049 Ingolstadt, Germany; University of St. Gallen, Institute of Technology Management, Dufourstrasse 40a, CH-9000 St. Gallen, Switzerland.
Drug discovery today
|August 3, 2024
概括
领先的制药公司显示,在2014-2023年期间,美国食品和药物管理局 (FDA) 的新药批准量有所下降. 这一趋势表明研究和开发 (R&D) 创新和市场竞争力的潜在损失.
科学领域:
- 制药行业分析分析 制药行业分析
- 药物开发和创新 药物开发和创新
- 监管科学是一种监管科学.
背景情况:
- 制药行业在保持研发 (R&D) 生产率方面面临着持续的挑战.
- 通过批准新药来评估研发成果对于评估公司绩效至关重要.
- 美国食品和药物管理局 (FDA) 在药物进入市场方面发挥着关键作用.
研究的目的:
- 分析顶级制药公司的研发生产率.
- 评估2014年至2023年FDA批准新药的趋势.
- 评估领先公司批准的新药的创新程度.
主要方法:
- 对20家顶级制药公司的FDA对新药批准的数据收集.
- 对涵盖2014-2023年期间的批准数据的分析.
- 评估批准的新药的创新性.
主要成果:
- 在2014-2023年期间,主要制药公司的新药批准数量显著下降.
- 分析表明,一些顶级制药公司的研发创新可能有所下降.
- 这一趋势引发了对这些公司持续的竞争优势和长期市场成功的担忧.
结论:
- 美国食品和药物管理局 (FDA) 批准的新药的下降表明,主要制药公司面临着潜在的研发生产率挑战.
- 制药公司可能正在经历其创新产出的减少,影响未来的市场可行性.
- 维持竞争优势和商业模式可能需要解决研发创新的下降问题.
相关概念视频
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Bioequivalence: Overview
955
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
955
Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
Prescription, Nonprescription and Orphan Drugs
711
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
711
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K

